Saltar al contenido
Merck

RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression.

Cancer research (2020-10-18)
Srinivasa P Kolapalli, Rinku Sahu, Nishant R Chauhan, Kautilya K Jena, Subhash Mehto, Saroj K Das, Ashish Jain, Manaswini Rout, Rupesh Dash, Rajeeb K Swain, David Y Lee, Tor Erik Rusten, Santosh Chauhan, Swati Chauhan
RESUMEN

DZIP3/hRUL138 is a poorly characterized RNA-binding RING E3-ubiquitin ligase with functions in embryonic development. Here we demonstrate that DZIP3 is a crucial driver of cancer cell growth, migration, and invasion. In mice and zebrafish cancer models, DZIP3 promoted tumor growth and metastasis. In line with these results, DZIP3 was frequently overexpressed in several cancer types. Depletion of DZIP3 from cells resulted in reduced expression of Cyclin D1 and a subsequent G1 arrest and defect in cell growth. Mechanistically, DZIP3 utilized its two different domains to interact and stabilize Cyclin D1 both at mRNA and protein levels. Using an RNA-binding lysine-rich region, DZIP3 interacted with the AU-rich region in 3' untranslated region of Cyclin D1 mRNA and stabilized it. Using a RING E3-ligase domain, DZIP3 interacted and increased K63-linked ubiquitination of Cyclin D1 protein to stabilize it. Remarkably, DZIP3 interacted with, ubiquitinated, and stabilized Cyclin D1 predominantly in the G1 phase of the cell cycle, where it is needed for cell-cycle progression. In agreement with this, a strong positive correlation of mRNA expression between DZIP3 and Cyclin D1 in different cancer types was observed. Additionally, DZIP3 regulated several cell cycle proteins by modulating the Cyclin D1-E2F axes. Taken together, this study demonstrates for the first time that DZIP3 uses a unique two-pronged mechanism in its stabilization of Cyclin D1 to drive cell-cycle and cancer progression. SIGNIFICANCE: These findings show that DZIP3 is a novel driver of cell-cycle and cancer progression via its control of Cyclin D1 mRNA and protein stability in a cell-cycle phase-dependent manner. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/2/315/F1.large.jpg.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Cicloheximida, from microbial, ≥94% (TLC)
Sigma-Aldrich
Reactivos rojos para detección in situ Duolink®
Sigma-Aldrich
Fluoruro de fenilmetansulfonilo, ≥98.5% (GC)
Sigma-Aldrich
Timidina, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Nocodazole, ≥99% (TLC), powder
Sigma-Aldrich
MISSION® esiRNA, targeting human DZIP3